Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 17/20 | 0.83 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.83 |
| ▸ | CLK3 | P49761 | 14/20 | 0.83 |
| ▸ | ITK | Q08881 | 2/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18448626 | 0.91 | CLK2 (1.00) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18448953 | 0.90 | CLK2 (0.85) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18449030 | 0.86 | CLK2 (0.78) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18449221 | 0.86 | CLK2 (0.78) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18448217 | 0.85 | CLK2 (0.78) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18450150 | 0.85 | CLK2 (0.78) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18448378 | 0.85 | CLK2 (0.73) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18445025 | 0.84 | ITK (0.66) | CLK2DYRK1ACLK3ITKMAP4K1 | |
| SCHEMBL18448933 | 0.84 | CLK2 (0.76) | CLK2DYRK1ACLK3ITK | |
| SCHEMBL18445370 | 0.84 | CLK2 (0.59) | CLK2DYRK1ACLK3ITKMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | claimed |
| WO-2017024004-A1 | 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206909-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 2181/4885DYRK1A 775/4885CLK3 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.